The Acquired Resistance to Therapy Network (ARTNet), of @theNCI focuses on mechanisms of acquired resistance to cancer therapies & disease recurrence and integrates those findings through team science. Learn more at nciartnet.org and t.ly/ZbxF3

How do cancer-driving fusion proteins create their own vulnerabilities? A new #ARTNetPublication in @CR_AACR co-authored by Dr. Trever Bivona @BivonaLabUCSF shows that FET fusion oncoproteins impair ATM-mediated DNA damage repair, forcing tumors to rely on ATR signaling for survival. This collateral dependency may be exploited therapeutically with ATR inhibitors across multiple FET-rearranged cancers. pubmed.ncbi.nlm.nih.gov/4181… #CancerResearch #EwingSarcoma #DNARepair #PrecisionMedicine #ATRinhibitors

Delighted to share our @NatureCancer paper, out today, on determinants of ICB response in GBM (link in 🧵) With bulk and single-nucleus genomic profiling of 181 ICB-treated tumors, we found that tumor RNA subtype (and not TMB!) predicts survival and shapes acquired resistance.

🚀 Now live: rasinhibitors.com A continuously updated map of every RAS inhibitor & degrader in clinical development — 75 drugs, from Phase 1 to FDA approval. The entire clinical RAS pipeline at a glance, updated regularly. Feedback welcome! 👉 rasinhibitors.com

Now online: PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition doi.org/10.1158/0008-5472.CA…

At today’s Cell States, Metabolism & Inflammatory Microenvironment #ARTNetWGMeeting, Dr. Fatima Mechta-Grigoriou @FatimaMechta from Institut Curie presented her work on "Spatial determinants of stromal heterogeneity rriving resistance to immunotherapy in cancer". Her fascinating research sparked a lively discussion on how the tumor microenvironment shapes therapeutic response and resistance.

Dr. Brian Druker joined the Precision Signals podcast to discuss Gleevec, precision oncology, and the future of cancer research 🎙️ Listen: youtube.com/watch?v=4a4o122a…

🚀 Check this out — we’ve launched an AI for Cancer Webinar Catalog, updated weekly! nciartnet.org/en/resources/a… This curated catalog brings together AI in cancer research webinars from publicly available academic, industry, and professional organizations in one place. A great resource for staying current with the rapidly evolving AI-oncology landscape.

At today’s #ARTNetSCMeeting, co-chair Dr. Alan Hutson @Amherst73 of @RoswellPark provided network updates, and Dr. Ping Mu @PingMu_PhD of @YaleMed presented how his lab is leveraging AI tools to decode mechanisms of therapy resistance in prostate cancer.

🎙️ The inaugural episode of the ARTNet Podcast is now live! Listen here and share with colleagues, friends, and family: theartnetpodcast.riverside.c… Join moderator Dr. David Goodrich @RoswellPark and featured speaker Dr. Jeffrey Tyner @OHSUKnight as they discuss cancer resistance, tumor evolution, and ARTNet’s mission to advance collaborative resistance research in accessible, science-grounded language. #ARTNet #NCI #CancerPlasticity #CancerAcquiredResistance #cancerfighter @theNCI

Cancer type-specific variation in patterns of driver alterations across 50,000 tumors dlvr.it/TSWtCg

JYP0322, a highly selective and brain-penetrant ROS1 inhibitor, overcomes ROS1G2032R resistance mutation in NSCLC: The first-in-human phase 1 trial dlvr.it/TSVdn4

Choosing the right research model is critical to advancing rigorous, reproducible science. Learn how NIH supports the use of New Approach Methodologies (NAMs), including organoids, computational models, and real-world data: bit.ly/4u3hGfP

🎙️ The inaugural episode of the ARTNet Podcast is now live! Join moderator Dr. David Goodrich @RoswellPark and featured speaker Dr. Jeffrey Tyner @OHSUKnight as they discuss cancer resistance, tumor evolution, and ARTNet’s mission to advance collaborative resistance research in accessible, science-grounded language. Listen here and share with colleagues, friends, and family: theartnetpodcast.riverside.c… #ARTNet #NCI #CancerPlasticity #CancerAcquiredResistance #cancerfighter @theNCI

At today’s Functional Screens and Assays #ARTNetWGMeeting, Dr. Anton Windfelder @AntonGeorgeM from the Fraunhofer Institute for Molecular Biology shared fascinating research on host-pathogen interactions using caterpillars as a model organism. The presentation sparked a highly engaging discussion among participants. #ARTNet

Congratulations to Dr. Jiang! @Dadi_Jiang

Join the conversation shaping the future of cancer care at the NCI workshop “Precision in Practice: A Functional Medicine Workshop” on July 1-2, 2026 at @theNCI Shady Grove Campus and online. Day 1 will highlight the current state-of-the-art in functional precision medicine, featuring a keynote presentation by Dr. Anthony Letai @NCIDirector. Day 2 will focus on defining the key scientific questions that will shape the next decade of cancer care. The workshop will bring together leaders from academia, industry, government, and patient advocacy to accelerate the translation of functional precision oncology into clinical practice. Explore the draft agenda and register today: events.cancer.gov/OD/functio… #CancerResearch #PrecisionMedicine #FunctionalPrecisionMedicine #Oncology #CancerCare